A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

被引：58

作者：

Ikeda, Masafumi

Sung, Max W.

Kudo, Masatoshi

Kobayashi, Masahiro

Baron, Ari David

Finn, Richard S.

Kaneko, Shuichi

Zhu, Andrew X.

Kubota, Tomoki

Kraljevic, Silvija

Ishikawa, Kohei

Siegel, Abby B.

Kumada, Hiromitsu

Okusaka, Takuji

机构：

[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[2] Tisch Canc Inst Mt Sinai, New York, NY USA

[3] Kindai Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka, Japan

[4] Toranomon Gen Hosp, Tokyo, Japan

[5] Calif Pacif Med Ctr Res Inst, San Francisco, CA USA

[6] Univ Calif Los Angeles, Los Angeles, CA 90024 USA

[7] Kanazawa Univ Hosp, Kanazawa, Ishikawa 9201192, Japan

[8] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[9] Eisai & Co Ltd, Tokyo, Japan

[10] Eisai Ltd, Hatfield, Herts, England

[11] Merck Co Inc, Kenilworth, NJ USA

[12] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.4076

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4076

引用

页数：2